glp-1 cardiovascular outcomes news today Key outcome trials for RAs. Created with Cardiovascular, mortality, and kidney outcomes

Mounjaro, DailyMed (2026) FDA approves new medication for chronic weight management, US Food and Drug Administration (2023) Mounjaro, PDR Tirzepatide, StatPearls (2024) Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025), Healthcare (Basel, Switzerland) (2025) Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity, Sleep Medicine (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Additional information Communicated by Massimo Federici, M.D Publishers note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Eli Lillys Orforglipron Hits Target in Diabetes TrialOral GLP-1 Battle with Novo Nordisk Heats Up Key Takeaways 10.5% average weight loss in overweight/obese patients with Type 2 diabetes over ~72 weeks on orforglipron

Fortunately, there is a class of drugs known as GLP-1 agonists that have been shown to be effective in weight loss and may be particularly useful for PCOS patients

Semaglutide/GLP-1 augments your weight loss efforts by stimulating the release of insulin, which aids in the regulation of blood sugar levels and promotes fat burning

Peterhnsel C, Petroff D, Klinitzke G, Kersting A, Wagner B